3Packer M, Poole-Wilson PA. Comparative effects of low and high doses of the aniotensin-converting enzyme inhibitor, lisinopril, on mobidity and mortality in chronic heart failure. Circulation, 1999, 100(23) :2312-2318.
4Swedberg K, Leland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure : executive summary ( up date2005 ). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart,2005,26(11 ) :1115-1140.
5Metra M, Giubbin R, Nodari S, et al. Differential effects ofβ- block in paients with heart failure: a prospetive, randomized, double-blind comparison of the long-time effects of metoprolol versus carvedilol. Circulation ,2000,102 (5) :546-551.
6MER1T-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:metoprolol CR/XL randomized intervenetion trial in congestive heart failure( MER IT-HF). Lancet, 1999,353 (9169) : 2001-2007.
7Hjalmarson A, Goldstein S,Fagerberg B, et al. Effects of controlled- release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metopmlol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA, 20(i0,283(10) :1295-1302.
8CIBIS Investigators and Committees. A randomized trial of B-block- ade in heart failure: the Cardiac Insufficiency Bisoprolol Study ( CI- BIS). Circulation ,1994,90(4) :1765-1773.
9Colucci WS, Packer M, Bristow MR,et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 1996,94 ( 11 ) :2800-2806.
10Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:the CHARM-Ahernative Trial. Iancet,2003,362(9386) :772-776.
